ResourceDrug Discovery & Development
Targeted delivery of nucleic acid therapeutics with lipophilic modifiers
20 Oct 2026This whitepaper explores how lipophilic modifications can enhance the delivery, cellular uptake and tissue targeting of nucleic acid therapeutics such as siRNAs and antisense oligonucleotides. Discover how conjugates including GalNAc, fatty acids, cholesterol and tocopherol influence biodistribution, pharmacokinetics and delivery to hepatic and extrahepatic tissues. Explore the mechanisms behind receptor-mediated uptake, plasma protein binding and tissue-specific targeting strategies, along with practical guidance on selecting oligonucleotide modifications for therapeutic development and next-generation RNA-based medicines.
Resource details:
Resource type: Whitepaper
Page count: 16
Read time: 20 mins
Links
Tags
OligonucleotidesOligonucleotides are small nucleic acid polymers, usually less than 20 bases in length. Oligonucleotides can be made via enzymatic cleavage or more commonly by chemical synthesis with polymerases. Their use includes FISH, southern blots, microarrays and as primers in PCR. High fidelity synthesis kits and detection systems are available for easy production and detection, respectively.RNARNA is a nucleic acid that plays a key role in gene expression and protein synthesis. It serves as a messenger between DNA and ribosomes, carrying genetic instructions to produce proteins. Advances in RNA-based therapies, such as mRNA vaccines and gene editing, have revolutionized treatment strategies for genetic disorders and infectious diseases. Explore RNA research tools and therapies in our peer-reviewed product directory; compare products, check customer reviews, and get pricing directly from manufacturers.